GSK announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Over 5,500 rare diseases have been identified(1) of which less than 10% are currently being treated(2), presenting a significant unmet medical need. Despite the rarity of each condition, the number of diseases means that between 6-8% of the population(3) may be affected by a rare disease. Many are genetic in origin, start in childhood and cause lifelong debility and premature death...
More...
More...